Market research
KIN Kindred Biosciences Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 421M
- P/E ratio
- Not available
- Analyst target
- 9.5
- Dividend yield
- 0.0%
- Beta
- 1.32
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US4945771099
- Market cap
- 421M
- P/E ratio
- Not available
- Analyst target
- 9.5
- Dividend yield
- 0.0%
- Beta
- 1.32
About
About Kindred Biosciences Inc
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California. As of August 27, 2021, Kindred Biosciences, Inc. operates as a subsidiary of Elanco Animal Health Incorporated.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the KIN discussion.
5 years, 4 months ago
Kindred Biosciences, Inc is currently in a long term uptrend where the price is trading 81.9% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.8.
Kindred Biosciences, Inc's total revenue sank by 32.1% to $951K since the same quarter in the previous year.
Its net income has increased by 30.7% to $-11M since the same quarter in the previous year.
Finally, its free cash flow grew by 51.8% to $-7M since the same quarter in the previous year.
Based on the above factors, Kindred Biosciences, Inc gets an overall score of 4/5.